Publication

Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire

Schreuder, N., de Hoog, Q., de Vries, S. T., Jager, P. L., Kosterink, J. G. W. & van Puijenbroek, E. P., Apr-2020, In : Drug Safety. 43, 4, p. 319-328 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Schreuder, N., de Hoog, Q., de Vries, S. T., Jager, P. L., Kosterink, J. G. W., & van Puijenbroek, E. P. (2020). Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire. Drug Safety, 43(4), 319-328. https://doi.org/10.1007/s40264-019-00895-2

Author

Schreuder, Nanno ; de Hoog, Quincy ; de Vries, Sieta T ; Jager, Pieter L ; Kosterink, Jos G W ; van Puijenbroek, Eugène P. / Patient-Reported Adverse Events of Radiopharmaceuticals : Development and Validation of a Questionnaire. In: Drug Safety. 2020 ; Vol. 43, No. 4. pp. 319-328.

Harvard

Schreuder, N, de Hoog, Q, de Vries, ST, Jager, PL, Kosterink, JGW & van Puijenbroek, EP 2020, 'Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire', Drug Safety, vol. 43, no. 4, pp. 319-328. https://doi.org/10.1007/s40264-019-00895-2

Standard

Patient-Reported Adverse Events of Radiopharmaceuticals : Development and Validation of a Questionnaire. / Schreuder, Nanno; de Hoog, Quincy; de Vries, Sieta T; Jager, Pieter L; Kosterink, Jos G W; van Puijenbroek, Eugène P.

In: Drug Safety, Vol. 43, No. 4, 04.2020, p. 319-328.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Schreuder N, de Hoog Q, de Vries ST, Jager PL, Kosterink JGW, van Puijenbroek EP. Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire. Drug Safety. 2020 Apr;43(4):319-328. https://doi.org/10.1007/s40264-019-00895-2


BibTeX

@article{b3cd8c0aca784d4aa7c88cb2e593ff01,
title = "Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire",
abstract = "Introduction Radiopharmaceuticals may cause adverse events. Knowledge about adverse events from a patient's perspective could help healthcare professionals to detect, understand, and manage adverse events more efficiently when using radiopharmaceuticals. Researchers need a validated questionnaire that can be used in patients to assess adverse events with radiopharmaceuticals. Objective The aim of this study was to develop, validate the content of, and perform initial testing of a questionnaire assessing patient-reported adverse events of radiopharmaceuticals. Methods Based on existing literature, six professionals drafted and evaluated a first version of the questionnaire. Further content validation was performed using cognitive interviews with six patients undergoing a nuclear medicine examination. After adaptations, the questionnaire was developed into a web-based questionnaire. One hundred patients undergoing nuclear examination tested this version, and the results were used to assess its acceptability and evaluate reported adverse events. Results Questions and answer options were revised in the initial questionnaire to improve clarity. In addition, some questions were removed. The final version consisted of 18 questions. In the test phase, the acceptability of the questionnaire was demonstrated (e.g. 79% of the patients who received the questionnaire completed it, and the median time to complete the questionnaire was 12 min for patients who reported an adverse event). Of the 100 patients (53% men, median age 64 years), 12 reported a total of 22 adverse events. One of these adverse events had a high causal association. Conclusion After validation and testing, the developed questionnaire to study patient-reported adverse events of radiopharmaceuticals is a suitable and valid instrument which can be used in future research.",
keywords = "PREVALENCE, CRITERIA, OUTCOMES, QUALITY",
author = "Nanno Schreuder and {de Hoog}, Quincy and {de Vries}, {Sieta T} and Jager, {Pieter L} and Kosterink, {Jos G W} and {van Puijenbroek}, {Eug{\`e}ne P}",
year = "2020",
month = apr,
doi = "10.1007/s40264-019-00895-2",
language = "English",
volume = "43",
pages = "319--328",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "ADIS INT LTD",
number = "4",

}

RIS

TY - JOUR

T1 - Patient-Reported Adverse Events of Radiopharmaceuticals

T2 - Development and Validation of a Questionnaire

AU - Schreuder, Nanno

AU - de Hoog, Quincy

AU - de Vries, Sieta T

AU - Jager, Pieter L

AU - Kosterink, Jos G W

AU - van Puijenbroek, Eugène P

PY - 2020/4

Y1 - 2020/4

N2 - Introduction Radiopharmaceuticals may cause adverse events. Knowledge about adverse events from a patient's perspective could help healthcare professionals to detect, understand, and manage adverse events more efficiently when using radiopharmaceuticals. Researchers need a validated questionnaire that can be used in patients to assess adverse events with radiopharmaceuticals. Objective The aim of this study was to develop, validate the content of, and perform initial testing of a questionnaire assessing patient-reported adverse events of radiopharmaceuticals. Methods Based on existing literature, six professionals drafted and evaluated a first version of the questionnaire. Further content validation was performed using cognitive interviews with six patients undergoing a nuclear medicine examination. After adaptations, the questionnaire was developed into a web-based questionnaire. One hundred patients undergoing nuclear examination tested this version, and the results were used to assess its acceptability and evaluate reported adverse events. Results Questions and answer options were revised in the initial questionnaire to improve clarity. In addition, some questions were removed. The final version consisted of 18 questions. In the test phase, the acceptability of the questionnaire was demonstrated (e.g. 79% of the patients who received the questionnaire completed it, and the median time to complete the questionnaire was 12 min for patients who reported an adverse event). Of the 100 patients (53% men, median age 64 years), 12 reported a total of 22 adverse events. One of these adverse events had a high causal association. Conclusion After validation and testing, the developed questionnaire to study patient-reported adverse events of radiopharmaceuticals is a suitable and valid instrument which can be used in future research.

AB - Introduction Radiopharmaceuticals may cause adverse events. Knowledge about adverse events from a patient's perspective could help healthcare professionals to detect, understand, and manage adverse events more efficiently when using radiopharmaceuticals. Researchers need a validated questionnaire that can be used in patients to assess adverse events with radiopharmaceuticals. Objective The aim of this study was to develop, validate the content of, and perform initial testing of a questionnaire assessing patient-reported adverse events of radiopharmaceuticals. Methods Based on existing literature, six professionals drafted and evaluated a first version of the questionnaire. Further content validation was performed using cognitive interviews with six patients undergoing a nuclear medicine examination. After adaptations, the questionnaire was developed into a web-based questionnaire. One hundred patients undergoing nuclear examination tested this version, and the results were used to assess its acceptability and evaluate reported adverse events. Results Questions and answer options were revised in the initial questionnaire to improve clarity. In addition, some questions were removed. The final version consisted of 18 questions. In the test phase, the acceptability of the questionnaire was demonstrated (e.g. 79% of the patients who received the questionnaire completed it, and the median time to complete the questionnaire was 12 min for patients who reported an adverse event). Of the 100 patients (53% men, median age 64 years), 12 reported a total of 22 adverse events. One of these adverse events had a high causal association. Conclusion After validation and testing, the developed questionnaire to study patient-reported adverse events of radiopharmaceuticals is a suitable and valid instrument which can be used in future research.

KW - PREVALENCE

KW - CRITERIA

KW - OUTCOMES

KW - QUALITY

U2 - 10.1007/s40264-019-00895-2

DO - 10.1007/s40264-019-00895-2

M3 - Article

C2 - 31916082

VL - 43

SP - 319

EP - 328

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 4

ER -

ID: 111895842